No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy
Background/Objectives Anthracyclines are used in induction therapy of pediatric acute lymphoblastic leukemia (ALL) and are known to generate oxidative stress; whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose‐6‐phosphate dehydrogenase (G6PD) de...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2019-06, Vol.66 (6), p.e27681-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 6 |
| container_start_page | e27681 |
| container_title | Pediatric blood & cancer |
| container_volume | 66 |
| creator | Robinson, Katherine M. Yang, Wenjian Karol, Seth E. Kornegay, Nancy Jay, Dennis Cheng, Cheng Choi, John K. Campana, Dario Pui, Ching‐Hon Wood, Brent Borowitz, Michael J. Gastier‐Foster, Julie Larsen, Eric C. Winick, Naomi Carroll, William L. Loh, Mignon L. Raetz, Elizabeth A. Hunger, Stephen P. Devidas, Meenakshi Mardis, Elaine R. Fulton, Robert S. Relling, Mary V. Jeha, Sima |
| description | Background/Objectives
Anthracyclines are used in induction therapy of pediatric acute lymphoblastic leukemia (ALL) and are known to generate oxidative stress; whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is unknown.
Design/Methods
Among 726 pediatric patients with newly diagnosed ALL treated at St. Jude Children's Research Hospital, 22 had deficient G6PD activity. We compared the prevalence of positive minimal residual disease (MRD) ≥1% at Day 15/Day 19 of induction or ≥0.01% at Day 42/Day 46 (end of induction) and the number of red blood cell (RBC) transfusions after daunorubicin in induction between patients with or without G6PD deficiency, adjusting for ALL risk group, treatment protocol, age, and gender.
Results
There was no difference in Day 15/19 (P = 1) or end of induction MRD (P = 0.76) nor in the number of RBC transfusions (P = 0.73); the lack of association with MRD was confirmed in a dataset of 1192 newly diagnosed male patients enrolled in a Children's Oncology Group trial (P = 0.78).
Conclusion
We found no evidence that G6PD deficiency affects daunorubicin activity during induction treatment for ALL. |
| doi_str_mv | 10.1002/pbc.27681 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6518412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2189531458</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4151-87fa985b8ed4110676fa7b0580944594765efd188d37393b073c477664ef0dd53</originalsourceid><addsrcrecordid>eNp1kU1vFSEYhYmxsR-68A8Ylrq4LdzhazYm9trWJo12oWvCwIsXnRlGYGpm2X8u9dYbXZiQ8OachwPkIPSSklNKyPps6uzpWgpFn6AjyhlfcULl0_1M2kN0nPO3igrC1TN02BDFFBH8CN1_jBjugoPRAi5bU_CVuH2PHfhgQxUXbLwHW3I1AYOvsqliTDgbD6VOHjszjzHNXT0x4rqMnQvgfhmmbex6k0uwuIf5OwzBVN_NtoQ4PgQmMy3P0YE3fYYXj_sJ-nJ58XnzYXXz6ep68-5mZRnldKWkN63inQLHKCVCCm9kV79DWsZ4y6Tg4B1VyjWyaZuOyMYyKYVg4IlzvDlBb3e509wN4CyMJZleTykMJi06mqD_dcaw1V_jnRacKkbXNeD1Y0CKP2bIRQ8hW-h7M0Kcs15T1fKGMq4q-maH2hRzTuD311CiHyrTtTL9u7LKvvr7XXvyT0cVONsBP0MPy_-T9O35Zhf5C07Iolw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2189531458</pqid></control><display><type>article</type><title>No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Robinson, Katherine M. ; Yang, Wenjian ; Karol, Seth E. ; Kornegay, Nancy ; Jay, Dennis ; Cheng, Cheng ; Choi, John K. ; Campana, Dario ; Pui, Ching‐Hon ; Wood, Brent ; Borowitz, Michael J. ; Gastier‐Foster, Julie ; Larsen, Eric C. ; Winick, Naomi ; Carroll, William L. ; Loh, Mignon L. ; Raetz, Elizabeth A. ; Hunger, Stephen P. ; Devidas, Meenakshi ; Mardis, Elaine R. ; Fulton, Robert S. ; Relling, Mary V. ; Jeha, Sima</creator><creatorcontrib>Robinson, Katherine M. ; Yang, Wenjian ; Karol, Seth E. ; Kornegay, Nancy ; Jay, Dennis ; Cheng, Cheng ; Choi, John K. ; Campana, Dario ; Pui, Ching‐Hon ; Wood, Brent ; Borowitz, Michael J. ; Gastier‐Foster, Julie ; Larsen, Eric C. ; Winick, Naomi ; Carroll, William L. ; Loh, Mignon L. ; Raetz, Elizabeth A. ; Hunger, Stephen P. ; Devidas, Meenakshi ; Mardis, Elaine R. ; Fulton, Robert S. ; Relling, Mary V. ; Jeha, Sima</creatorcontrib><description>Background/Objectives
Anthracyclines are used in induction therapy of pediatric acute lymphoblastic leukemia (ALL) and are known to generate oxidative stress; whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is unknown.
Design/Methods
Among 726 pediatric patients with newly diagnosed ALL treated at St. Jude Children's Research Hospital, 22 had deficient G6PD activity. We compared the prevalence of positive minimal residual disease (MRD) ≥1% at Day 15/Day 19 of induction or ≥0.01% at Day 42/Day 46 (end of induction) and the number of red blood cell (RBC) transfusions after daunorubicin in induction between patients with or without G6PD deficiency, adjusting for ALL risk group, treatment protocol, age, and gender.
Results
There was no difference in Day 15/19 (P = 1) or end of induction MRD (P = 0.76) nor in the number of RBC transfusions (P = 0.73); the lack of association with MRD was confirmed in a dataset of 1192 newly diagnosed male patients enrolled in a Children's Oncology Group trial (P = 0.78).
Conclusion
We found no evidence that G6PD deficiency affects daunorubicin activity during induction treatment for ALL.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.27681</identifier><identifier>PMID: 30848065</identifier><language>eng</language><publisher>United States</publisher><subject>Antibiotics, Antineoplastic - therapeutic use ; Child ; Cohort Studies ; daunorubicin ; Daunorubicin - therapeutic use ; doxorubicin ; Female ; Follow-Up Studies ; Glucosephosphate Dehydrogenase - metabolism ; glucose‐6‐phospate dehydrogenase ; Humans ; Induction Chemotherapy ; leukemia ; Male ; Neoadjuvant Therapy ; Neoplasm, Residual - drug therapy ; Neoplasm, Residual - enzymology ; Neoplasm, Residual - pathology ; pharmacogenetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology ; Prognosis ; Risk Factors ; Safety</subject><ispartof>Pediatric blood & cancer, 2019-06, Vol.66 (6), p.e27681-n/a</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4151-87fa985b8ed4110676fa7b0580944594765efd188d37393b073c477664ef0dd53</citedby><cites>FETCH-LOGICAL-c4151-87fa985b8ed4110676fa7b0580944594765efd188d37393b073c477664ef0dd53</cites><orcidid>0000-0003-1550-4167 ; 0000-0002-3720-9591 ; 0000-0003-0303-5658</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.27681$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.27681$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30848065$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robinson, Katherine M.</creatorcontrib><creatorcontrib>Yang, Wenjian</creatorcontrib><creatorcontrib>Karol, Seth E.</creatorcontrib><creatorcontrib>Kornegay, Nancy</creatorcontrib><creatorcontrib>Jay, Dennis</creatorcontrib><creatorcontrib>Cheng, Cheng</creatorcontrib><creatorcontrib>Choi, John K.</creatorcontrib><creatorcontrib>Campana, Dario</creatorcontrib><creatorcontrib>Pui, Ching‐Hon</creatorcontrib><creatorcontrib>Wood, Brent</creatorcontrib><creatorcontrib>Borowitz, Michael J.</creatorcontrib><creatorcontrib>Gastier‐Foster, Julie</creatorcontrib><creatorcontrib>Larsen, Eric C.</creatorcontrib><creatorcontrib>Winick, Naomi</creatorcontrib><creatorcontrib>Carroll, William L.</creatorcontrib><creatorcontrib>Loh, Mignon L.</creatorcontrib><creatorcontrib>Raetz, Elizabeth A.</creatorcontrib><creatorcontrib>Hunger, Stephen P.</creatorcontrib><creatorcontrib>Devidas, Meenakshi</creatorcontrib><creatorcontrib>Mardis, Elaine R.</creatorcontrib><creatorcontrib>Fulton, Robert S.</creatorcontrib><creatorcontrib>Relling, Mary V.</creatorcontrib><creatorcontrib>Jeha, Sima</creatorcontrib><title>No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>Background/Objectives
Anthracyclines are used in induction therapy of pediatric acute lymphoblastic leukemia (ALL) and are known to generate oxidative stress; whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is unknown.
Design/Methods
Among 726 pediatric patients with newly diagnosed ALL treated at St. Jude Children's Research Hospital, 22 had deficient G6PD activity. We compared the prevalence of positive minimal residual disease (MRD) ≥1% at Day 15/Day 19 of induction or ≥0.01% at Day 42/Day 46 (end of induction) and the number of red blood cell (RBC) transfusions after daunorubicin in induction between patients with or without G6PD deficiency, adjusting for ALL risk group, treatment protocol, age, and gender.
Results
There was no difference in Day 15/19 (P = 1) or end of induction MRD (P = 0.76) nor in the number of RBC transfusions (P = 0.73); the lack of association with MRD was confirmed in a dataset of 1192 newly diagnosed male patients enrolled in a Children's Oncology Group trial (P = 0.78).
Conclusion
We found no evidence that G6PD deficiency affects daunorubicin activity during induction treatment for ALL.</description><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Child</subject><subject>Cohort Studies</subject><subject>daunorubicin</subject><subject>Daunorubicin - therapeutic use</subject><subject>doxorubicin</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glucosephosphate Dehydrogenase - metabolism</subject><subject>glucose‐6‐phospate dehydrogenase</subject><subject>Humans</subject><subject>Induction Chemotherapy</subject><subject>leukemia</subject><subject>Male</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm, Residual - drug therapy</subject><subject>Neoplasm, Residual - enzymology</subject><subject>Neoplasm, Residual - pathology</subject><subject>pharmacogenetics</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</subject><subject>Prognosis</subject><subject>Risk Factors</subject><subject>Safety</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1vFSEYhYmxsR-68A8Ylrq4LdzhazYm9trWJo12oWvCwIsXnRlGYGpm2X8u9dYbXZiQ8OachwPkIPSSklNKyPps6uzpWgpFn6AjyhlfcULl0_1M2kN0nPO3igrC1TN02BDFFBH8CN1_jBjugoPRAi5bU_CVuH2PHfhgQxUXbLwHW3I1AYOvsqliTDgbD6VOHjszjzHNXT0x4rqMnQvgfhmmbex6k0uwuIf5OwzBVN_NtoQ4PgQmMy3P0YE3fYYXj_sJ-nJ58XnzYXXz6ep68-5mZRnldKWkN63inQLHKCVCCm9kV79DWsZ4y6Tg4B1VyjWyaZuOyMYyKYVg4IlzvDlBb3e509wN4CyMJZleTykMJi06mqD_dcaw1V_jnRacKkbXNeD1Y0CKP2bIRQ8hW-h7M0Kcs15T1fKGMq4q-maH2hRzTuD311CiHyrTtTL9u7LKvvr7XXvyT0cVONsBP0MPy_-T9O35Zhf5C07Iolw</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Robinson, Katherine M.</creator><creator>Yang, Wenjian</creator><creator>Karol, Seth E.</creator><creator>Kornegay, Nancy</creator><creator>Jay, Dennis</creator><creator>Cheng, Cheng</creator><creator>Choi, John K.</creator><creator>Campana, Dario</creator><creator>Pui, Ching‐Hon</creator><creator>Wood, Brent</creator><creator>Borowitz, Michael J.</creator><creator>Gastier‐Foster, Julie</creator><creator>Larsen, Eric C.</creator><creator>Winick, Naomi</creator><creator>Carroll, William L.</creator><creator>Loh, Mignon L.</creator><creator>Raetz, Elizabeth A.</creator><creator>Hunger, Stephen P.</creator><creator>Devidas, Meenakshi</creator><creator>Mardis, Elaine R.</creator><creator>Fulton, Robert S.</creator><creator>Relling, Mary V.</creator><creator>Jeha, Sima</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1550-4167</orcidid><orcidid>https://orcid.org/0000-0002-3720-9591</orcidid><orcidid>https://orcid.org/0000-0003-0303-5658</orcidid></search><sort><creationdate>201906</creationdate><title>No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy</title><author>Robinson, Katherine M. ; Yang, Wenjian ; Karol, Seth E. ; Kornegay, Nancy ; Jay, Dennis ; Cheng, Cheng ; Choi, John K. ; Campana, Dario ; Pui, Ching‐Hon ; Wood, Brent ; Borowitz, Michael J. ; Gastier‐Foster, Julie ; Larsen, Eric C. ; Winick, Naomi ; Carroll, William L. ; Loh, Mignon L. ; Raetz, Elizabeth A. ; Hunger, Stephen P. ; Devidas, Meenakshi ; Mardis, Elaine R. ; Fulton, Robert S. ; Relling, Mary V. ; Jeha, Sima</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4151-87fa985b8ed4110676fa7b0580944594765efd188d37393b073c477664ef0dd53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Child</topic><topic>Cohort Studies</topic><topic>daunorubicin</topic><topic>Daunorubicin - therapeutic use</topic><topic>doxorubicin</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glucosephosphate Dehydrogenase - metabolism</topic><topic>glucose‐6‐phospate dehydrogenase</topic><topic>Humans</topic><topic>Induction Chemotherapy</topic><topic>leukemia</topic><topic>Male</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm, Residual - drug therapy</topic><topic>Neoplasm, Residual - enzymology</topic><topic>Neoplasm, Residual - pathology</topic><topic>pharmacogenetics</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology</topic><topic>Prognosis</topic><topic>Risk Factors</topic><topic>Safety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robinson, Katherine M.</creatorcontrib><creatorcontrib>Yang, Wenjian</creatorcontrib><creatorcontrib>Karol, Seth E.</creatorcontrib><creatorcontrib>Kornegay, Nancy</creatorcontrib><creatorcontrib>Jay, Dennis</creatorcontrib><creatorcontrib>Cheng, Cheng</creatorcontrib><creatorcontrib>Choi, John K.</creatorcontrib><creatorcontrib>Campana, Dario</creatorcontrib><creatorcontrib>Pui, Ching‐Hon</creatorcontrib><creatorcontrib>Wood, Brent</creatorcontrib><creatorcontrib>Borowitz, Michael J.</creatorcontrib><creatorcontrib>Gastier‐Foster, Julie</creatorcontrib><creatorcontrib>Larsen, Eric C.</creatorcontrib><creatorcontrib>Winick, Naomi</creatorcontrib><creatorcontrib>Carroll, William L.</creatorcontrib><creatorcontrib>Loh, Mignon L.</creatorcontrib><creatorcontrib>Raetz, Elizabeth A.</creatorcontrib><creatorcontrib>Hunger, Stephen P.</creatorcontrib><creatorcontrib>Devidas, Meenakshi</creatorcontrib><creatorcontrib>Mardis, Elaine R.</creatorcontrib><creatorcontrib>Fulton, Robert S.</creatorcontrib><creatorcontrib>Relling, Mary V.</creatorcontrib><creatorcontrib>Jeha, Sima</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robinson, Katherine M.</au><au>Yang, Wenjian</au><au>Karol, Seth E.</au><au>Kornegay, Nancy</au><au>Jay, Dennis</au><au>Cheng, Cheng</au><au>Choi, John K.</au><au>Campana, Dario</au><au>Pui, Ching‐Hon</au><au>Wood, Brent</au><au>Borowitz, Michael J.</au><au>Gastier‐Foster, Julie</au><au>Larsen, Eric C.</au><au>Winick, Naomi</au><au>Carroll, William L.</au><au>Loh, Mignon L.</au><au>Raetz, Elizabeth A.</au><au>Hunger, Stephen P.</au><au>Devidas, Meenakshi</au><au>Mardis, Elaine R.</au><au>Fulton, Robert S.</au><au>Relling, Mary V.</au><au>Jeha, Sima</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2019-06</date><risdate>2019</risdate><volume>66</volume><issue>6</issue><spage>e27681</spage><epage>n/a</epage><pages>e27681-n/a</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>Background/Objectives
Anthracyclines are used in induction therapy of pediatric acute lymphoblastic leukemia (ALL) and are known to generate oxidative stress; whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is unknown.
Design/Methods
Among 726 pediatric patients with newly diagnosed ALL treated at St. Jude Children's Research Hospital, 22 had deficient G6PD activity. We compared the prevalence of positive minimal residual disease (MRD) ≥1% at Day 15/Day 19 of induction or ≥0.01% at Day 42/Day 46 (end of induction) and the number of red blood cell (RBC) transfusions after daunorubicin in induction between patients with or without G6PD deficiency, adjusting for ALL risk group, treatment protocol, age, and gender.
Results
There was no difference in Day 15/19 (P = 1) or end of induction MRD (P = 0.76) nor in the number of RBC transfusions (P = 0.73); the lack of association with MRD was confirmed in a dataset of 1192 newly diagnosed male patients enrolled in a Children's Oncology Group trial (P = 0.78).
Conclusion
We found no evidence that G6PD deficiency affects daunorubicin activity during induction treatment for ALL.</abstract><cop>United States</cop><pmid>30848065</pmid><doi>10.1002/pbc.27681</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-1550-4167</orcidid><orcidid>https://orcid.org/0000-0002-3720-9591</orcidid><orcidid>https://orcid.org/0000-0003-0303-5658</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2019-06, Vol.66 (6), p.e27681-n/a |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6518412 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibiotics, Antineoplastic - therapeutic use Child Cohort Studies daunorubicin Daunorubicin - therapeutic use doxorubicin Female Follow-Up Studies Glucosephosphate Dehydrogenase - metabolism glucose‐6‐phospate dehydrogenase Humans Induction Chemotherapy leukemia Male Neoadjuvant Therapy Neoplasm, Residual - drug therapy Neoplasm, Residual - enzymology Neoplasm, Residual - pathology pharmacogenetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Prognosis Risk Factors Safety |
| title | No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T14%3A35%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20evidence%20that%20G6PD%20deficiency%20affects%20the%20efficacy%20or%20safety%20of%20daunorubicin%20in%20acute%20lymphoblastic%20leukemia%20induction%20therapy&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Robinson,%20Katherine%20M.&rft.date=2019-06&rft.volume=66&rft.issue=6&rft.spage=e27681&rft.epage=n/a&rft.pages=e27681-n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.27681&rft_dat=%3Cproquest_pubme%3E2189531458%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2189531458&rft_id=info:pmid/30848065&rfr_iscdi=true |